Looks like Strong turn-outs on the Nico-Lab roadshows this week.
The HealthTech sector is looking like a good area to be invested in the coming years, and Nico-Lab is in position to capitalise.
A few points that caught my attention:
- CE approved.
- TGA approved
- Integrated into many EU hospitals.
- 15+ USA hospitals trialling.
- FDA application being processed
- Generous government grants received to expand tech capabilities
- High margin given algorithm driven solution
- Scalable
- Opportunities to expand into other areas of the body
- Founders & Management still owns circa 50% of shares.
- Plenty of M&A activity within the sector
- Partnerships with some blue chip companies
- Asia roadshow next week.
